Applied dna sciences inc (APDN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10
Cash flows from operating activities:
Net loss

-2,950

-2,662

-

-

-2,686

-3,234

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-2,887

-2,146

-3,183

-2,854

-2,610

-3,428

-3,961

-2,415

-3,367

-3,467

-2,926

-496

-1,670

-1,885

-7,828

-2,105

-1,919

-2,750

-6,291

-3,718

-2,135

-3,127

-8,704

-1,767

-1,429

-1,543

-2,409

-4,417

-2,154

-2,598

-1,344

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

66

75

70

87

97

135

121

122

145

157

146

161

163

161

148

168

170

218

136

121

123

109

116

113

106

105

101

62

21

20

13

103

98

98

90

91

91

92

Stock-based compensation

227

205

217

154

267

490

1,171

238

-285

231

695

566

537

1,458

594

557

489

396

491

1,015

517

1,998

315

404

547

765

182

461

455

417

389

1,506

56

1

-

-

229

225

Fair value of vested options issued to officers, directors and employees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

389

785

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

519

6,332

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-2,994

-

515

455

-2,634

-

-

-

-

-

-

-

-

-

-

-

-

Loss on conversion of promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,961

0

0

-980

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

13

-

-

-

-

-

-

-

-

Common stock issued for consulting services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

9

10

58

-

-

-

-

0

0

0

337

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of vested options issued to officers, directors and employees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

157

148

Amortization of debt issuance costs

-

6

9

4

4

4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

3

82

127

271

268

191

Amortization of debt discount attributable to convertible debentures

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

33

507

547

562

835

150

Common stock issued in settlement of interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-405

0

393

114

2

2

5

27

Provision for bad debts

0

0

16

0

0

-8

-

-

-

-

55

346

15

5

10

83

12

10

13

18

0

2

2

0

1

15

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Accounts receivable

275

-565

612

-72

-298

-879

70

-107

-612

-432

-1,507

74

-823

-828

2,768

209

-384

4

3,360

946

45

282

319

-86

-142

91

92

249

46

64

-145

119

91

24

30

78

36

-0

Inventories

6

-59

-167

-4

89

3

-73

1

-20

-12

-50

22

29

26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets and deposits

73

13

60

-46

-31

-6

32

27

35

173

253

-69

50

-66

405

-8

-26

-71

19

34

6

18

-33

60

-11

-47

32

131

-27

-27

-27

84

-26

-13

-26

50

-38

-55

Accounts payable and accrued liabilities

369

-793

283

227

-41

198

142

221

102

-39

-191

-3

-290

-124

336

-130

-137

-320

1,316

223

-44

-253

235

-52

109

234

-98

398

0

216

628

-9

-398

19

-548

377

-12

-16

Deferred revenue

216

-173

-173

-402

-170

18

-441

1,093

861

-8

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-322

-298

-370

-477

1,888

798

-7

-224

77

-22

-296

-59

234

-67

91

176

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-2,420

-2,731

-1,776

-1,283

-2,288

-1,513

-2,508

-1,128

-706

-2,572

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Purchase of property and equipment

8

0

-1

4

11

52

-3

66

155

48

34

17

51

42

78

466

76

51

129

23

167

30

20

99

15

94

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-2,630

-2,068

-2,446

-2,226

-2,502

-2,720

-1,739

-1,255

-1,615

-2,355

-2,241

-2,008

-2,196

-2,066

-2,173

-1,807

-2,148

-1,740

-992

-1,124

-1,032

-811

-1,561

-710

-1,020

-469

Purchase of intangible asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69

6

23

14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-44

0

1

-4

-11

-52

3

-66

-155

-48

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from Promissory notes (related parties $550,000)

0

0

-

0

0

550

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of secured convertible promissory notes

-

107

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-51

-42

-147

-472

-94

-66

-1,678

-226

-202

-30

-20

-99

-15

-94

-423

-767

-30

0

-97

-18

-47

0

-

-

-

0

Net proceeds from sale of common stock and warrants

-303

10,942

-0

-15

-14

2,493

0

0

-193

4,425

1,505

266

0

4,333

0

0

0

7,853

0

11,158

0

7,956

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from (payments of) related party advances

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-600

600

0

-50

Net proceeds from sale of common stock and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,900

0

0

2,000

-

-

-

-

-

-

-

-

Purchase and cancelation of previously issued warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

4,090

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

250

0

675

970

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

4,333

-13

0

0

7,857

0

11,227

-69

3,865

-

-

-

-

7,125

1

5,600

2,000

-

-

-

-

4,385

600

675

920

Net cash provided by financing activities

2,464

10,835

1,827

253

703

3,043

1,650

0

-193

4,425

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

0

8,103

-

-

-1,596

1,478

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-1,194

-1,055

1,804

556

-1,617

-2,681

2,222

-2,607

-2,699

-2,597

5,070

-3,417

9,746

-1,887

1,478

-632

37

-2,211

-2,160

4,528

-2,573

3,421

259

-531

399

-1,079

-811

2,734

-110

-345

450

Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Cash paid during period for income taxes

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-4

4

0

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Non-cash investing and financing activities:
Impact of adoption of new accounting pronouncements included in accumulated deficit

0

0

0

0

0

493

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid in kind (related party of $35,550 for the six month period ended March 31, 2019)

0

35

61

16

48

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued upon cashless exercise of options and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of deferred offering costs to additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs incurred, and included in accounts payable

-303

303

99

-15

-215

231

-

-

-

192

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment acquired, and included in accounts payable

-

-

-

-

-

-

-

8

-15

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend-warrant repricing

0

2

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock and warrants issued upon conversion of promissory notes payable and accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

665

0

2,872

1,150

-16

37

55

297

Property and equipment acquired, and included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

376

40

-12

-167

0

181

-

-

-0

8

-

-

-

-

-

-

-

-

-

-

-

-

Intangible assets acquired, and included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

54

-11

17

-

-43

73

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of options to settle accrued liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

42

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued for cashless exercise of options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-19

0

0

18

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs reclassified to additional paid in capital

0

109

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-